High FAM189B Expression and Its Prognostic Value in Patients with Gastric Cancer. 2021

Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
Department of Gastroenterology, Guangxi International Zhuang Medicine Hospital, Nanning, 530200 Guangxi, China.

The clinical significance of the family with sequence similarity 189 member B (FAM189B) gene remains largely unknown in gastric cancer (GC). A comprehensive investigation combining multiple detection methods was carried out in the current study to unveil the clinical implications and prospective molecular characterization of FAM189B protein and mRNA in GC. The protein level of FAM189B was clearly upregulated in the tumor tissues of GC as compared to noncancerous gastric tissues with 179 GC cases and 147 noncancerous gastric controls assessed by immunohistochemistry. The upregulation of the FAM189B protein was also found in the more deteriorating period of the tumor, as there were increasing trends in the groups of larger tumors, with lymph node metastasis, a further advanced clinical stage, and a higher histological grade. Next, we focused on the mRNA level of FAM189B in GC tissues using various high-throughput data. After the screening of GEO, ArrayExpress, and SRA, we finally achieved 18 datasets, including an RNA sequencing dataset of TCGA. Altogether, 1095 cases of GC tissue samples were collected, with 305 unique examples of noncancerous controls. Concerning the mRNA level of FAM189B in GC, the final standard mean difference (SMD) was 0.46 and the area under the curve (AUC) was 0.79 for the upregulation of FAM189B mRNA, which confirmed that the FAM189B mRNA level was also markedly upregulated in GC tissues and comparable to its protein level. The survival analysis showed that the higher expression of FAM189B was a risk factor for the overall survival, first progression, and postprogression survival of GC. For the Affymetrix ID 1555515_a_at of FAM189B, the higher expression level of FAM189B predicted a lower overall survival, first progression survival, and postprogression survival with the hazard ratio (HR) being 1.56 (1.24, 1.95), 1.69 (1.32, 2.17), and 1.97 (1.5, 2.6), respectively. For the Affymetrix ID 203550_s_at of FAM189B, a similar result could be found with corresponding HR being 1.49 (1.24, 1.8), 1.49 (1.21, 1.83), and 1.66 (1.32, 2.08), respectively. The interaction of MEM, COXPRESdb coexpressed genes, and DEGs of GC finally generated 368 genes, and the pathway of the cell cycle was the top pathway enriched by KEGG. In conclusion, the overexpression of the FAM189B protein and mRNA might enhance the incidence of GC.

UI MeSH Term Description Entries
D008297 Male Males
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D018572 Disease-Free Survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. Survival, Disease-Free,Disease Free Survival,Survival, Disease Free

Related Publications

Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
May 2017, Pathology, research and practice,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
April 2018, Medical science monitor : international medical journal of experimental and clinical research,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
September 2005, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
November 2013, Molecular biology reports,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
July 2016, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
October 2022, Aging,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
December 2018, World journal of surgery,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
May 2021, BMC cancer,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
July 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Chang-Liang Wu, and Quan-Xiao Tan, and Dan Liu, and Jun-E Jiang, and Ting Lu, and Zu-Mei Huang, and Ying-Jie Su
July 2022, Annals of clinical and laboratory science,
Copied contents to your clipboard!